HBIO Stock Analysis: Buy, Sell, or Hold?
HBIO - Harvard Bioscience Inc
$7.48
-0.07 (-0.93%)
▼
5d:
+12.4%
30d:
+20.84%
90d:
+35.51%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When HBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HBIO is 10.5% above its trading range ($6.77). Market expects 6.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HBIO is 10.5% above its trading range ($6.77). Market expects 6.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.59
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.33
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HBIO is currently trading at $7.48, which is considered extended relative to its 30-day fair value range of $5.92 to $6.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.6) compared to its historical average (9.5). At these levels, the market is pricing in 6.9% annual earnings growth.
Technical Outlook: Technically, HBIO is in a uptrend. The price is approaching resistance at $7.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HBIO is in a uptrend. The price is approaching resistance at $7.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.92 -
$6.77
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
17.6%
All Signals
- BEARISH: Price significantly overextended (+10.5% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($7.50)
- BULLISH: Expecting earnings turnaround to 6.9% growth with 11.1% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.92 -
$6.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.05
Resistance Level
$7.64
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.60
Wall Street Target
$7.50
(+0.3%)
Revenue Growth (YoY)
11.1%
Earnings Growth (YoY)
-80.3%
Profit Margin
-11.9%
Valuation Premium vs History
+6.9% premium
PE vs Historical
11.6 vs 9.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.9%
(market-implied from PE analysis)
1-Year Target
$8.00
(+7%)
2-Year Target
$8.55
(+14%)
3-Year Target
$9.14
(+22%)
3-Yr Target (if PE normalizes)
(PE: 12→10)
PE COMPRESSION
$7.49
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 22, 2026 10:27 PM ET
Data refreshes hourly during market hours. Next update: 11:27 PM
Data refreshes hourly during market hours. Next update: 11:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HBIO showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Stephen J Denelsky
BUY
10000 shares
2026-03-17
William Snider
BUY
8475 shares
2026-03-17
John D Duke
BUY
5000 shares
2026-03-16
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 46 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$86 | 37 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 66 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 45 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$247 | 41 HOLD |
